Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05849922 · ClinicalTrials.gov registry record · Phase 2
A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa
A Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 20
- Study locations
NCT05849922: Completed Phase 2 study of Hidradenitis Suppurativa, sponsored by Sanofi.
NCT05849922 is a Phase 2 study of Hidradenitis Suppurativa that has completed, run by Sanofi. The registered enrollment target is 86 participants, below the 596-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05849922, a Phase 2 study of Hidradenitis Suppurativa, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
Primary Outcome
The HiSCR50 was used for assessing HS treatment effectiveness in controlling inflammatory manifestations in the population. HiSCR50 was defined as \>=50% reduction from baseline in the total abscess and inflammatory nodule (AN) count, with no increase from baseline in abscess or draining tunnel count. Baseline was defined as the last available value before the first dose of DB study drug. Percentages are rounded off to the tenth decimal place.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SAR442970
Study Locations (20)
Other
- Investigational Site Number : 0560001 - Leuven
- Investigational Site Number : 1240007 - Québec
- Investigational Site Number : 2030003 - Ostrava - Poruba
- Investigational Site Number : 2030001 - Prague
- Investigational Site Number : 2030002 - Praha 5 - Motol
- Investigational Site Number : 2080001 - Roskilde
Ontario
- Investigational Site Number : 1240001 - Barrie
- Investigational Site Number : 1240002 - London
- Investigational Site Number : 1240004 - Newmarket
Reg Metropolitana de Santiago
- Investigational Site Number : 1520003 - Santiago
- Investigational Site Number : 1520001 - Santiago
- Investigational Site Number : 1520002 - Santiago
Florida
- Renstar Medical Research Site Number : 8400011 - Ocala
- ForCare Clinical Research Site Number : 8400006 - Tampa
Arizona
- Medical Dermatology Specialists Site Number : 8400007 - Phoenix
Georgia
- Advanced Medical Research PC Site Number : 8400002 - Sandy Springs
Rhode Island
- Clinical Partners, LLC Site Number : 8400010 - Johnston
Texas
- Center for Clinical Studies, LTD. LLP Site Number : 8400003 - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2025-01-09 |
| Phase | Phase 2 |
What the finished NCT05849922 record still lists
NCT05849922 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 596-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (86% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05849922 names 20 study sites across 10 states, led by Other, Ontario, Reg Metropolitana de Santiago.
Frequently Asked Questions
What is clinical trial NCT05849922 about?
NCT05849922 is a clinical study titled "A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa". This was a Phase 2 study in adult participants with moderate to severe hidradenitis suppurativa (HS). The purpose of the study was to evaluate the efficacy and safety of SAR442970 compared to placebo.
What is the current status of trial NCT05849922?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2023-06-06. Estimated completion is 2025-01-09.
What conditions does trial NCT05849922 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT05849922?
The interventions under investigation include: Placebo (DRUG), SAR442970 (DRUG).
Who is sponsoring clinical trial NCT05849922?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05849922 being conducted?
This trial has 20 study locations across Arizona, Florida, Georgia, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05849922's enrollment target sits among peer trials
86 29th of 52 higher than 24 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
RECRUITING · Phase 2
-
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
-
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI